9 results for tag: profiteering
A new medical study has found that the latest new cancer drugs are being sold for many times the costs spent developing them; resulting in mega profits for the drug companies who own them and restricted access to these drugs for only the wealthiest patients and healthcare providers.
When we give money to cancer research charities like Cancer Research UK we expect that money to be used efficiently but less than 2% is likely to be spent on researching new drugs that can be given to NHS cancer patients as a routine treatment.
Our medical R&D system is undermining our health – reform could boost our economy and our wellbeing. It’s time we implemented a new, more efficient, collaboratively driven, open innovation model with patient needs at its heart.
Half of new cancer drugs are too pricey for the NHS due to profiteering by drug companies. The Government is choosing to leave patients to die early rather than exercise its legal powers to obtain the newer, more effective drugs from a cheaper alternative source.
The cost of developing new cancer drugs could be halved at least if we cooperated across the world to publicly fund R&D, using cheaper finance, eliminating wasteful duplication and developing drugs for public benefit not for profit.
With support for the Dying for a Cure campaign growing, a letter has been sent today to the Secretary of State for Health, Jeremy Hunt, setting out the issues and sharing with him a sample of comments from supporters.
A shocking new study has revealed pharmaceutical companies have been fined more than £25bn over the last 25 years for illegal activity aimed at boosting profits. Patients are ultimately paying the price for this through higher drug prices.
Shocking new evidence has come to light of massive profiteering from cancer drugs - one cancer drug that costs only £99 to make is being being sold for up to £83,000, despite R&D costs being paid back over 10 years years ago.
News about a promising new breast cancer treatment combining Herceptin and Tyverb is dampened by the prospect that the drugs may be too expensive for the NHS.